For much of the past decade, venture capital firms and other investors were eager to throw money at biotech startups in hopes of bankrolling the next billion-dollar medicine. These days, fledgling drugmakers spend as much time convincing investors they have enough cash to survive as they do developing the promising treatments in their pipelines.
How often are biotech executives questioned about cash? "Every single conversation," says Marcio Souza, chief executive officer of Praxis Precision Medicines Inc. Shares of the company, which aims to treat central nervous system disorders, have plummeted 80% over the past year.
Investors today want to know how much money companies have, how long it will last and exactly how they plan to use it, executives say. The answers are especially important in 2023, as investors navigate a tough environment for risky assets, such as biotech stocks, and hundreds of companies seek to raise fresh funds to stay in business.
It's a stark turn of events for an industry that got used to big capital influxes before and during the pandemic. VC firms invested a record $36.6 billion in biopharma companies in the US, UK and European Union in 2021, up 281% from 2017, according to SVB, the parent of Silicon Valley Bank. Private investment in 2022 dipped 19% from the year before, to $29.5 billion. The slump speaks to growing investor uncertainty about biotech's near-term prospects.
All that money spawned hundreds of new biotech companies a year. At the peak, 357 were funded in 2021, up from 202 in 2017, according to an SVB analysis of seed and Series A deals in the US and Europe. Such exuberance spread to the stock market, where more than 100 biotechs went public in 2021 alone, including companies that were selling investors on a dream rather than data.
Bu hikaye Bloomberg Businessweek US dergisinin January 23, 2023 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye Bloomberg Businessweek US dergisinin January 23, 2023 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Giriş Yap
Instagram's Founders Say It's Time for a New Social App
The rise of AI and the fall of Twitter could create opportunities for upstarts
Running in Circles
A subscription running shoe program aims to fight footwear waste
What I Learned Working at a Hawaiien Mega-Resort
Nine wild secrets from the staff at Turtle Bay, who have to manage everyone from haughty honeymooners to go-go-dancing golfers.
How Noma Will Blossom In Kyoto
The best restaurant in the world just began its second pop-up in Japan. Here's what's cooking
The Last-Mover Problem
A startup called Sennder is trying to bring an extremely tech-resistant industry into the age of apps
Tick Tock, TikTok
The US thinks the Chinese-owned social media app is a major national security risk. TikTok is running out of ways to avoid a ban
Cleaner Clothing Dye, Made From Bacteria
A UK company produces colors with less water than conventional methods and no toxic chemicals
Pumping Heat in Hamburg
The German port city plans to store hot water underground and bring it up to heat homes in the winter
Sustainability: Calamari's Climate Edge
Squid's ability to flourish in warmer waters makes it fitting for a diet for the changing environment
New Money, New Problems
In Naples, an influx of wealthy is displacing out-of-towners lower-income workers